Zobrazeno 1 - 9 of 9 pro vyhledávání: '"Fawzi Adab"'
1
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
Autor: Joanna Gale, C.L. Ferguson, J. Martin Russell, Prabir Chakraborti, Carys Thomas, Mohan Hingorani, Joe M. O'Sullivan, Anjali Zarkar, Clare Gilson, Zafar Malik, John Wagstaff, Jo Bowen, Fiona McKinna, Angus Robinson, Claire Amos, Simon Chowdhury, Alison Birtle, Fawzi Adab, Peter Hoskin, San Aung, Robin Millman, Chris Parker, Neil McPhail, Alastair W. S. Ritchie, Robert Jones, Jason F. Lester, Noel W. Clarke, Susannah Brock, Gerhardt Attard, Andrew Protheroe, James D. Wylie, Omi Parikh, Johann S. de Bono, Nicholas D. James, Julian Money-Kyrle, Malcolm David Mason, William Cross, Emma Gray, David Matheson, Dominik Berthold, Silke Gillessen, Melissa R. Spears, David P. Dearnaley, Narayanan Srihari, Matthew R. Sydes, Mahesh K.B. Parmar, Chris Brawley
Publikováno v: STAMPEDE investigators 2017, ' Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy ', New England Journal of Medicine, vol. 377, no. 4, pp. 338-351 . https://doi.org/10.1056/NEJMoa1702900
STAMPEDE Investigators & Gillessen, S 2017, ' Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy ', The New England Journal of Medicine, vol. 377, no. 4, pp. 338-351 . https://doi.org/10.1056/NEJMoa1702900
The New England journal of medicine, vol. 377, no. 4, pp. 338-351
BACKGROUND: Abiraterone acetate plus prednisolone improves survival in men with relapsed prostate cancer. We assessed the effect of this combination in men starting long-term androgen-deprivation therapy (ADT), using a multigroup, multistage trial de
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ae654176b4379045bb5aaa6609f18434
https://pure.qub.ac.uk/en/publications/bca063cc-7a5e-46eb-95d8-7e27f2cf88b6
Zobrazit plný text záznamu
2
Randomized Noninferiority Trial of Reduced High-Dose Volume Versus Standard Volume Radiation Therapy for Muscle-Invasive Bladder Cancer: Results of the BC2001 Trial (CRUK/01/004)
Autor: Isabel Syndikus, Emma Hall, Rebecca Lewis, Fawzi Adab, D. Sheehan, Jean Tremlett, Carey Hendron, Peter Jenkins, Rachel Waters, Christine Rawlings, Syed A. Hussain, Robert Huddart, Malcolm Crundwell, Nicholas D. James
Publikováno v: International Journal of Radiation Oncology, Biology, Physics
Purpose To test whether reducing radiation dose to uninvolved bladder while maintaining dose to the tumor would reduce side effects without impairing local control in the treatment of muscle-invasive bladder cancer. Methods and Materials In this phas
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dd6092e1d1b0fa9289f170338a425bdc
https://doi.org/10.1016/j.ijrobp.2013.06.2044
Zobrazit plný text záznamu
3
Best time to assess complete clinical response after chemoradiotherapy in squamous cell carcinoma of the anus (ACT II): a post-hoc analysis of randomised controlled phase 3 trial
Autor: Robert, Glynne-Jones, David, Sebag-Montefiore, Helen M, Meadows, David, Cunningham, Rubina, Begum, Fawzi, Adab, Kim, Benstead, Robert J, Harte, Jill, Stewart, Sandy, Beare, Allan, Hackshaw, Latha, Kadalayil
Publikováno v: The Lancet. Oncology. 18(3)
Guidelines for anal cancer recommend assessment of response at 6-12 weeks after starting treatment. Using data from the ACT II trial, we determined the optimum timepoint to assess clinical tumour response after chemoradiotherapy.The previously report
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::f9087cea468ae423fa481b1ea802c8d6
https://pubmed.ncbi.nlm.nih.gov/33152308
Zobrazit plný text záznamu
5
Modified de Gramont with oxaliplatin in the first-line treatment of advanced colorectal cancer
Autor: Heather Anderson, Michael Braun, J Stewart, Mark P Saunders, A. C. McDonald, S. F. Davies, J Bozzino, C Twelves, N J Wadd, Karen McAdam, C Bradley, Matthew T. Seymour, Fawzi Adab, C MacMillan, F. J. Richards, Angus Robinson, George Thomas, R Counsell, D.W. Rea, R Philips
Publikováno v: British Journal of Cancer
We previously reported high activity for oxaliplatin and a modified de Gramont regimen (OxMdG) in a single centre study of patients with metastatic colorectal cancer. We now report results with a further 56 patients treated at 14 centres. Low rates o
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::47914cf64cd37888b9ec15bd850649da
https://doi.org/10.1038/sj.bjc.6601237
Zobrazit plný text záznamu
6
Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer
Autor: Juan W. Valle, Joe Ostrowski, Janet A. Dunn, Fawzi Adab, David Cunningham, Stephen Falk, William P. Steward, Ian Chau, Julia M. West, Richard Herrmann, Werner Scheithauer, Peter Harper, David Smith, Martin Eatock, Pauline Leonard, John P. Neoptolemos, Joyce Thompson, Deborah D. Stocken, Catrin Tudur-Smith, Adrian Crellin
Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(33)
Purpose Both gemcitabine (GEM) and fluoropyrimidines are valuable treatment for advanced pancreatic cancer. This open-label study was designed to compare the overall survival (OS) of patients randomly assigned to GEM alone or GEM plus capecitabine (G
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::efe8e6d8329c958fe27b9a7de627fe54
https://pubmed.ncbi.nlm.nih.gov/19858387
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje